Effect of Alendronate on Vascular Calcification in CKD Stages 3 and 4: A Pilot Randomized Controlled Trial
Background Vascular calcification contributes to cardiovascular disease in patients with chronic kidney disease (CKD). Few studies have addressed interventions to decrease vascular calcification; however, experimental studies report benefits of bisphosphonates. Recent studies of hemodialysis patient...
Gespeichert in:
Veröffentlicht in: | American journal of kidney diseases 2010-07, Vol.56 (1), p.57-68 |
---|---|
Hauptverfasser: | , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 68 |
---|---|
container_issue | 1 |
container_start_page | 57 |
container_title | American journal of kidney diseases |
container_volume | 56 |
creator | Toussaint, Nigel D., MBBS, FRACP, PhD Lau, Kenneth K., MBBS, FRANZCR Strauss, Boyd J., MBBS, FRACP, PhD Polkinghorne, Kevan R., MBChB, FRACP, PhD Kerr, Peter G., MBBS, FRACP, PhD |
description | Background Vascular calcification contributes to cardiovascular disease in patients with chronic kidney disease (CKD). Few studies have addressed interventions to decrease vascular calcification; however, experimental studies report benefits of bisphosphonates. Recent studies of hemodialysis patients also suggest benefits of bisphosphonates on vascular calcification; however, no study exists in nondialysis patients with CKD. Study Design We conducted a randomized controlled trial to determine the effect of bisphosphonates on vascular calcification in patients with CKD. Setting & Participants 51 patients with CKD stages 3-4 were recruited from a hospital outpatient setting; 50 were treated with study medication. Interventions Patients were randomly assigned to either alendronate, 70 mg (n = 25), or matching placebo (n = 25), administered weekly. Outcomes The primary outcome was change in aortic vascular calcification after 18 months. Secondary outcomes included superficial femoral artery vascular calcification, arterial compliance, bone mineral density (BMD), renal function, and serum markers of mineral metabolism. Measurements At baseline and 12 and 18 months, computed tomography, pulse wave velocity using SphygmoCor (AtCor Medical, PWV Inc, www.atcormedical.com ), and dual-energy x-ray absorptiometry were performed to measure vascular calcification, arterial compliance, and BMD, respectively. Analysis was by intention to treat, with a random-effect linear regression model to assess differences. Results 46 patients completed the study (24 alendronate, 22 placebo); baseline mean age was 63.1 ± 1.8 years, estimated glomerular filtration rate was 34.5 ± 1.4 mL/min/1.73 m2 , 59% had diabetes, and 65% were men. 91% had aortic vascular calcification at the start and 78% showed progression. At 18 months, there was no difference in vascular calcification progression with alendronate compared with placebo (adjusted difference, −24.2 Hounsfield units [95% CI, −77.0 to 28.6]; P = 0.4). There was an increase in lumbar spine BMD (T score difference, +0.3 [95% CI, 0.03-0.6]; P = 0.04) and a trend toward better pulse wave velocity (−1 m/s [95% CI, −2.1 to 0.1]; P = 0.07) with alendronate. Femoral BMD was similar between groups. There was a nonsignificant decrease in kidney function in patients on alendronate therapy compared with placebo (−1.2 mL/min/1.73 m2 [95% CI, −4.0 to 1.7]). Limitations Small sample size and baseline differences, especially with aortic vascular ca |
doi_str_mv | 10.1053/j.ajkd.2009.12.039 |
format | Article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_733978830</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>1_s2_0_S0272638610001186</els_id><sourcerecordid>733978830</sourcerecordid><originalsourceid>FETCH-LOGICAL-c506t-6e384cb941b630461c9be9dc6f32b1f7405931b5e970ab3375ca983a1fbb30cc3</originalsourceid><addsrcrecordid>eNp9kk2L1TAUhoMozp3RP-BCshFXvSY5bdqICJfO-IEDijO6DWmaSDq5yZi0wvjrTblXBReu8sHznoTnHISeULKlpIEX01ZNN-OWESK2lG0JiHtoQxsGFe-gu482hLWs4tDxE3Sa80QKCJw_RCeMQN02lG7QdGGt0TOOFu-8CWOKQc0Gx4C_qqwXrxLuldfOOq1mV65dwP2Hc3w1q28mY8AqjLh-iXf4k_Nxxp_LOe7dTzPiPoY5Re_L9jo55R-hB1b5bB4f1zP05c3Fdf-uuvz49n2_u6x0Q_hccQNdrQdR04EDqTnVYjBi1NwCG6hta9IIoENjREvUANA2WokOFLXDAERrOEPPD3VvU_y-mDzLvcvaeK-CiUuWLYBouw5IIdmB1CnmnIyVt8ntVbqTlMhVsZzkqliuiiVlsiguoafH8suwN-OfyG-nBXh2BIpB5W1SQbv8l2Oi5bRZX3914EyR8cOZJLN2JmgzulRaIsfo_v-P1__EtXehtMnfmDuTp7ikUDRLKnMJyKt1GNZZoGUMKO04_AIlwqzz</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>733978830</pqid></control><display><type>article</type><title>Effect of Alendronate on Vascular Calcification in CKD Stages 3 and 4: A Pilot Randomized Controlled Trial</title><source>MEDLINE</source><source>Access via ScienceDirect (Elsevier)</source><creator>Toussaint, Nigel D., MBBS, FRACP, PhD ; Lau, Kenneth K., MBBS, FRANZCR ; Strauss, Boyd J., MBBS, FRACP, PhD ; Polkinghorne, Kevan R., MBChB, FRACP, PhD ; Kerr, Peter G., MBBS, FRACP, PhD</creator><creatorcontrib>Toussaint, Nigel D., MBBS, FRACP, PhD ; Lau, Kenneth K., MBBS, FRANZCR ; Strauss, Boyd J., MBBS, FRACP, PhD ; Polkinghorne, Kevan R., MBChB, FRACP, PhD ; Kerr, Peter G., MBBS, FRACP, PhD</creatorcontrib><description>Background Vascular calcification contributes to cardiovascular disease in patients with chronic kidney disease (CKD). Few studies have addressed interventions to decrease vascular calcification; however, experimental studies report benefits of bisphosphonates. Recent studies of hemodialysis patients also suggest benefits of bisphosphonates on vascular calcification; however, no study exists in nondialysis patients with CKD. Study Design We conducted a randomized controlled trial to determine the effect of bisphosphonates on vascular calcification in patients with CKD. Setting & Participants 51 patients with CKD stages 3-4 were recruited from a hospital outpatient setting; 50 were treated with study medication. Interventions Patients were randomly assigned to either alendronate, 70 mg (n = 25), or matching placebo (n = 25), administered weekly. Outcomes The primary outcome was change in aortic vascular calcification after 18 months. Secondary outcomes included superficial femoral artery vascular calcification, arterial compliance, bone mineral density (BMD), renal function, and serum markers of mineral metabolism. Measurements At baseline and 12 and 18 months, computed tomography, pulse wave velocity using SphygmoCor (AtCor Medical, PWV Inc, www.atcormedical.com ), and dual-energy x-ray absorptiometry were performed to measure vascular calcification, arterial compliance, and BMD, respectively. Analysis was by intention to treat, with a random-effect linear regression model to assess differences. Results 46 patients completed the study (24 alendronate, 22 placebo); baseline mean age was 63.1 ± 1.8 years, estimated glomerular filtration rate was 34.5 ± 1.4 mL/min/1.73 m2 , 59% had diabetes, and 65% were men. 91% had aortic vascular calcification at the start and 78% showed progression. At 18 months, there was no difference in vascular calcification progression with alendronate compared with placebo (adjusted difference, −24.2 Hounsfield units [95% CI, −77.0 to 28.6]; P = 0.4). There was an increase in lumbar spine BMD (T score difference, +0.3 [95% CI, 0.03-0.6]; P = 0.04) and a trend toward better pulse wave velocity (−1 m/s [95% CI, −2.1 to 0.1]; P = 0.07) with alendronate. Femoral BMD was similar between groups. There was a nonsignificant decrease in kidney function in patients on alendronate therapy compared with placebo (−1.2 mL/min/1.73 m2 [95% CI, −4.0 to 1.7]). Limitations Small sample size and baseline differences, especially with aortic vascular calcification, may have diminished any potential difference between groups. Conclusions Unlike previous studies of hemodialysis patients, alendronate did not decrease the progression of vascular calcification compared with placebo in patients with CKD during 18 months.</description><identifier>ISSN: 0272-6386</identifier><identifier>EISSN: 1523-6838</identifier><identifier>DOI: 10.1053/j.ajkd.2009.12.039</identifier><identifier>PMID: 20347511</identifier><language>eng</language><publisher>New York, NY: Elsevier Inc</publisher><subject>Aged ; Alendronate ; Alendronate - pharmacology ; Alendronate - therapeutic use ; Aorta - drug effects ; Aorta - pathology ; Biological and medical sciences ; bisphosphonates ; bone mineral density ; Calcinosis - drug therapy ; Calcinosis - pathology ; cardiovascular disease ; chronic kidney disease ; Female ; Humans ; Kidney - blood supply ; Kidney - drug effects ; Kidney - pathology ; Kidney Failure, Chronic - drug therapy ; Kidney Failure, Chronic - pathology ; Kidneys ; Male ; Medical sciences ; Middle Aged ; mineral metabolism ; Nephrology ; Nephrology. Urinary tract diseases ; Nephropathies. Renovascular diseases. Renal failure ; Pilot Projects ; Renal failure ; Urinary system involvement in other diseases. Miscellaneous ; vascular calcification ; Vascular Diseases - drug therapy ; Vascular Diseases - pathology</subject><ispartof>American journal of kidney diseases, 2010-07, Vol.56 (1), p.57-68</ispartof><rights>National Kidney Foundation, Inc.</rights><rights>2010 National Kidney Foundation, Inc.</rights><rights>2015 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c506t-6e384cb941b630461c9be9dc6f32b1f7405931b5e970ab3375ca983a1fbb30cc3</citedby><cites>FETCH-LOGICAL-c506t-6e384cb941b630461c9be9dc6f32b1f7405931b5e970ab3375ca983a1fbb30cc3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1053/j.ajkd.2009.12.039$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,780,784,3550,27924,27925,45995</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=22976150$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/20347511$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Toussaint, Nigel D., MBBS, FRACP, PhD</creatorcontrib><creatorcontrib>Lau, Kenneth K., MBBS, FRANZCR</creatorcontrib><creatorcontrib>Strauss, Boyd J., MBBS, FRACP, PhD</creatorcontrib><creatorcontrib>Polkinghorne, Kevan R., MBChB, FRACP, PhD</creatorcontrib><creatorcontrib>Kerr, Peter G., MBBS, FRACP, PhD</creatorcontrib><title>Effect of Alendronate on Vascular Calcification in CKD Stages 3 and 4: A Pilot Randomized Controlled Trial</title><title>American journal of kidney diseases</title><addtitle>Am J Kidney Dis</addtitle><description>Background Vascular calcification contributes to cardiovascular disease in patients with chronic kidney disease (CKD). Few studies have addressed interventions to decrease vascular calcification; however, experimental studies report benefits of bisphosphonates. Recent studies of hemodialysis patients also suggest benefits of bisphosphonates on vascular calcification; however, no study exists in nondialysis patients with CKD. Study Design We conducted a randomized controlled trial to determine the effect of bisphosphonates on vascular calcification in patients with CKD. Setting & Participants 51 patients with CKD stages 3-4 were recruited from a hospital outpatient setting; 50 were treated with study medication. Interventions Patients were randomly assigned to either alendronate, 70 mg (n = 25), or matching placebo (n = 25), administered weekly. Outcomes The primary outcome was change in aortic vascular calcification after 18 months. Secondary outcomes included superficial femoral artery vascular calcification, arterial compliance, bone mineral density (BMD), renal function, and serum markers of mineral metabolism. Measurements At baseline and 12 and 18 months, computed tomography, pulse wave velocity using SphygmoCor (AtCor Medical, PWV Inc, www.atcormedical.com ), and dual-energy x-ray absorptiometry were performed to measure vascular calcification, arterial compliance, and BMD, respectively. Analysis was by intention to treat, with a random-effect linear regression model to assess differences. Results 46 patients completed the study (24 alendronate, 22 placebo); baseline mean age was 63.1 ± 1.8 years, estimated glomerular filtration rate was 34.5 ± 1.4 mL/min/1.73 m2 , 59% had diabetes, and 65% were men. 91% had aortic vascular calcification at the start and 78% showed progression. At 18 months, there was no difference in vascular calcification progression with alendronate compared with placebo (adjusted difference, −24.2 Hounsfield units [95% CI, −77.0 to 28.6]; P = 0.4). There was an increase in lumbar spine BMD (T score difference, +0.3 [95% CI, 0.03-0.6]; P = 0.04) and a trend toward better pulse wave velocity (−1 m/s [95% CI, −2.1 to 0.1]; P = 0.07) with alendronate. Femoral BMD was similar between groups. There was a nonsignificant decrease in kidney function in patients on alendronate therapy compared with placebo (−1.2 mL/min/1.73 m2 [95% CI, −4.0 to 1.7]). Limitations Small sample size and baseline differences, especially with aortic vascular calcification, may have diminished any potential difference between groups. Conclusions Unlike previous studies of hemodialysis patients, alendronate did not decrease the progression of vascular calcification compared with placebo in patients with CKD during 18 months.</description><subject>Aged</subject><subject>Alendronate</subject><subject>Alendronate - pharmacology</subject><subject>Alendronate - therapeutic use</subject><subject>Aorta - drug effects</subject><subject>Aorta - pathology</subject><subject>Biological and medical sciences</subject><subject>bisphosphonates</subject><subject>bone mineral density</subject><subject>Calcinosis - drug therapy</subject><subject>Calcinosis - pathology</subject><subject>cardiovascular disease</subject><subject>chronic kidney disease</subject><subject>Female</subject><subject>Humans</subject><subject>Kidney - blood supply</subject><subject>Kidney - drug effects</subject><subject>Kidney - pathology</subject><subject>Kidney Failure, Chronic - drug therapy</subject><subject>Kidney Failure, Chronic - pathology</subject><subject>Kidneys</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>mineral metabolism</subject><subject>Nephrology</subject><subject>Nephrology. Urinary tract diseases</subject><subject>Nephropathies. Renovascular diseases. Renal failure</subject><subject>Pilot Projects</subject><subject>Renal failure</subject><subject>Urinary system involvement in other diseases. Miscellaneous</subject><subject>vascular calcification</subject><subject>Vascular Diseases - drug therapy</subject><subject>Vascular Diseases - pathology</subject><issn>0272-6386</issn><issn>1523-6838</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2010</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kk2L1TAUhoMozp3RP-BCshFXvSY5bdqICJfO-IEDijO6DWmaSDq5yZi0wvjrTblXBReu8sHznoTnHISeULKlpIEX01ZNN-OWESK2lG0JiHtoQxsGFe-gu482hLWs4tDxE3Sa80QKCJw_RCeMQN02lG7QdGGt0TOOFu-8CWOKQc0Gx4C_qqwXrxLuldfOOq1mV65dwP2Hc3w1q28mY8AqjLh-iXf4k_Nxxp_LOe7dTzPiPoY5Re_L9jo55R-hB1b5bB4f1zP05c3Fdf-uuvz49n2_u6x0Q_hccQNdrQdR04EDqTnVYjBi1NwCG6hta9IIoENjREvUANA2WokOFLXDAERrOEPPD3VvU_y-mDzLvcvaeK-CiUuWLYBouw5IIdmB1CnmnIyVt8ntVbqTlMhVsZzkqliuiiVlsiguoafH8suwN-OfyG-nBXh2BIpB5W1SQbv8l2Oi5bRZX3914EyR8cOZJLN2JmgzulRaIsfo_v-P1__EtXehtMnfmDuTp7ikUDRLKnMJyKt1GNZZoGUMKO04_AIlwqzz</recordid><startdate>20100701</startdate><enddate>20100701</enddate><creator>Toussaint, Nigel D., MBBS, FRACP, PhD</creator><creator>Lau, Kenneth K., MBBS, FRANZCR</creator><creator>Strauss, Boyd J., MBBS, FRACP, PhD</creator><creator>Polkinghorne, Kevan R., MBChB, FRACP, PhD</creator><creator>Kerr, Peter G., MBBS, FRACP, PhD</creator><general>Elsevier Inc</general><general>Elsevier</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20100701</creationdate><title>Effect of Alendronate on Vascular Calcification in CKD Stages 3 and 4: A Pilot Randomized Controlled Trial</title><author>Toussaint, Nigel D., MBBS, FRACP, PhD ; Lau, Kenneth K., MBBS, FRANZCR ; Strauss, Boyd J., MBBS, FRACP, PhD ; Polkinghorne, Kevan R., MBChB, FRACP, PhD ; Kerr, Peter G., MBBS, FRACP, PhD</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c506t-6e384cb941b630461c9be9dc6f32b1f7405931b5e970ab3375ca983a1fbb30cc3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2010</creationdate><topic>Aged</topic><topic>Alendronate</topic><topic>Alendronate - pharmacology</topic><topic>Alendronate - therapeutic use</topic><topic>Aorta - drug effects</topic><topic>Aorta - pathology</topic><topic>Biological and medical sciences</topic><topic>bisphosphonates</topic><topic>bone mineral density</topic><topic>Calcinosis - drug therapy</topic><topic>Calcinosis - pathology</topic><topic>cardiovascular disease</topic><topic>chronic kidney disease</topic><topic>Female</topic><topic>Humans</topic><topic>Kidney - blood supply</topic><topic>Kidney - drug effects</topic><topic>Kidney - pathology</topic><topic>Kidney Failure, Chronic - drug therapy</topic><topic>Kidney Failure, Chronic - pathology</topic><topic>Kidneys</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>mineral metabolism</topic><topic>Nephrology</topic><topic>Nephrology. Urinary tract diseases</topic><topic>Nephropathies. Renovascular diseases. Renal failure</topic><topic>Pilot Projects</topic><topic>Renal failure</topic><topic>Urinary system involvement in other diseases. Miscellaneous</topic><topic>vascular calcification</topic><topic>Vascular Diseases - drug therapy</topic><topic>Vascular Diseases - pathology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Toussaint, Nigel D., MBBS, FRACP, PhD</creatorcontrib><creatorcontrib>Lau, Kenneth K., MBBS, FRANZCR</creatorcontrib><creatorcontrib>Strauss, Boyd J., MBBS, FRACP, PhD</creatorcontrib><creatorcontrib>Polkinghorne, Kevan R., MBChB, FRACP, PhD</creatorcontrib><creatorcontrib>Kerr, Peter G., MBBS, FRACP, PhD</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>American journal of kidney diseases</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Toussaint, Nigel D., MBBS, FRACP, PhD</au><au>Lau, Kenneth K., MBBS, FRANZCR</au><au>Strauss, Boyd J., MBBS, FRACP, PhD</au><au>Polkinghorne, Kevan R., MBChB, FRACP, PhD</au><au>Kerr, Peter G., MBBS, FRACP, PhD</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Effect of Alendronate on Vascular Calcification in CKD Stages 3 and 4: A Pilot Randomized Controlled Trial</atitle><jtitle>American journal of kidney diseases</jtitle><addtitle>Am J Kidney Dis</addtitle><date>2010-07-01</date><risdate>2010</risdate><volume>56</volume><issue>1</issue><spage>57</spage><epage>68</epage><pages>57-68</pages><issn>0272-6386</issn><eissn>1523-6838</eissn><abstract>Background Vascular calcification contributes to cardiovascular disease in patients with chronic kidney disease (CKD). Few studies have addressed interventions to decrease vascular calcification; however, experimental studies report benefits of bisphosphonates. Recent studies of hemodialysis patients also suggest benefits of bisphosphonates on vascular calcification; however, no study exists in nondialysis patients with CKD. Study Design We conducted a randomized controlled trial to determine the effect of bisphosphonates on vascular calcification in patients with CKD. Setting & Participants 51 patients with CKD stages 3-4 were recruited from a hospital outpatient setting; 50 were treated with study medication. Interventions Patients were randomly assigned to either alendronate, 70 mg (n = 25), or matching placebo (n = 25), administered weekly. Outcomes The primary outcome was change in aortic vascular calcification after 18 months. Secondary outcomes included superficial femoral artery vascular calcification, arterial compliance, bone mineral density (BMD), renal function, and serum markers of mineral metabolism. Measurements At baseline and 12 and 18 months, computed tomography, pulse wave velocity using SphygmoCor (AtCor Medical, PWV Inc, www.atcormedical.com ), and dual-energy x-ray absorptiometry were performed to measure vascular calcification, arterial compliance, and BMD, respectively. Analysis was by intention to treat, with a random-effect linear regression model to assess differences. Results 46 patients completed the study (24 alendronate, 22 placebo); baseline mean age was 63.1 ± 1.8 years, estimated glomerular filtration rate was 34.5 ± 1.4 mL/min/1.73 m2 , 59% had diabetes, and 65% were men. 91% had aortic vascular calcification at the start and 78% showed progression. At 18 months, there was no difference in vascular calcification progression with alendronate compared with placebo (adjusted difference, −24.2 Hounsfield units [95% CI, −77.0 to 28.6]; P = 0.4). There was an increase in lumbar spine BMD (T score difference, +0.3 [95% CI, 0.03-0.6]; P = 0.04) and a trend toward better pulse wave velocity (−1 m/s [95% CI, −2.1 to 0.1]; P = 0.07) with alendronate. Femoral BMD was similar between groups. There was a nonsignificant decrease in kidney function in patients on alendronate therapy compared with placebo (−1.2 mL/min/1.73 m2 [95% CI, −4.0 to 1.7]). Limitations Small sample size and baseline differences, especially with aortic vascular calcification, may have diminished any potential difference between groups. Conclusions Unlike previous studies of hemodialysis patients, alendronate did not decrease the progression of vascular calcification compared with placebo in patients with CKD during 18 months.</abstract><cop>New York, NY</cop><pub>Elsevier Inc</pub><pmid>20347511</pmid><doi>10.1053/j.ajkd.2009.12.039</doi><tpages>12</tpages></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0272-6386 |
ispartof | American journal of kidney diseases, 2010-07, Vol.56 (1), p.57-68 |
issn | 0272-6386 1523-6838 |
language | eng |
recordid | cdi_proquest_miscellaneous_733978830 |
source | MEDLINE; Access via ScienceDirect (Elsevier) |
subjects | Aged Alendronate Alendronate - pharmacology Alendronate - therapeutic use Aorta - drug effects Aorta - pathology Biological and medical sciences bisphosphonates bone mineral density Calcinosis - drug therapy Calcinosis - pathology cardiovascular disease chronic kidney disease Female Humans Kidney - blood supply Kidney - drug effects Kidney - pathology Kidney Failure, Chronic - drug therapy Kidney Failure, Chronic - pathology Kidneys Male Medical sciences Middle Aged mineral metabolism Nephrology Nephrology. Urinary tract diseases Nephropathies. Renovascular diseases. Renal failure Pilot Projects Renal failure Urinary system involvement in other diseases. Miscellaneous vascular calcification Vascular Diseases - drug therapy Vascular Diseases - pathology |
title | Effect of Alendronate on Vascular Calcification in CKD Stages 3 and 4: A Pilot Randomized Controlled Trial |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-25T00%3A25%3A29IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Effect%20of%20Alendronate%20on%20Vascular%20Calcification%20in%20CKD%20Stages%203%20and%204:%20A%20Pilot%20Randomized%20Controlled%20Trial&rft.jtitle=American%20journal%20of%20kidney%20diseases&rft.au=Toussaint,%20Nigel%20D.,%20MBBS,%20FRACP,%20PhD&rft.date=2010-07-01&rft.volume=56&rft.issue=1&rft.spage=57&rft.epage=68&rft.pages=57-68&rft.issn=0272-6386&rft.eissn=1523-6838&rft_id=info:doi/10.1053/j.ajkd.2009.12.039&rft_dat=%3Cproquest_cross%3E733978830%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=733978830&rft_id=info:pmid/20347511&rft_els_id=1_s2_0_S0272638610001186&rfr_iscdi=true |